| 000 | 01712 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514010734.0 | ||
| 264 | 0 | _c20011004 | |
| 008 | 200110s 0 0 eng d | ||
| 022 | _a0169-5002 | ||
| 024 | 7 |
_a10.1016/s0169-5002(00)00240-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVidetic, G M | |
| 245 | 0 | 0 |
_aUsing treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _c |
||
| 300 |
_a249-58 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Small Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 |
_aEpirubicin _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 |
_aVincristine _xtherapeutic use |
| 700 | 1 | _aFung, K | |
| 700 | 1 | _aTomiak, A T | |
| 700 | 1 | _aStitt, L W | |
| 700 | 1 | _aDar, A R | |
| 700 | 1 | _aTruong, P T | |
| 700 | 1 | _aYu, E W | |
| 700 | 1 | _aVincent, M D | |
| 700 | 1 | _aKocha, W I | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 33 _gno. 2-3 _gp. 249-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0169-5002(00)00240-3 _zAvailable from publisher's website |
| 999 |
_c11473990 _d11473990 |
||